The investigational anti-interleukin-6 (IL-6) monoclonal antibody pacibekitug produced sustained reductions in inflammation-related biomarkers through six months in patients with chronic kidney disease and elevated inflammatory risk associated with heart disease.
These are the significant final findings from the "TRANQUILITY" phase 2 clinical trial evaluating the safety and efficacy of the therapy. The results were presented Aug. 29 in a Hot Line Session at the European Society of Cardiology Congress (ESC 2026) in Munich, Germany, by Deepak L. Bhatt, MD, MPH, director of Mount Sinai Fuster Heart Hospital.
"These findings demonstrate that durable suppression of the IL-6 pathway is achievable with infrequent dosing of a long-acting monoclonal antibody," Bhatt said. "The next critical step is to determine whether the effects observed in TRANQUILITY translate into improved cardiovascular outcomes in patients with elevated inflammatory cardiovascular risk."
Inflammation is increasingly recognized as an important contributor to cardiovascular disease. IL-6 is a signaling protein involved in inflammatory pathways that has been associated with cardiovascular risk. Pacibekitug is an investigational long-acting monoclonal antibody designed to target IL-6 and reduce inflammatory activity.
